Many tumour suppressors and oncoproteins use Crm1 for their nuclear export and, as the best-characterised nuclear export inhibitor, LMB has been a candidate for anti-cancer drug development, although it failed clinical trials due to toxicity. This evidence concerns the gene XPO1 and neoplasm.